Clinical Guidance for the Management of Patients with Urothelial Cancers During the COVID-19 Pandemic - Rapid Review. by Patel, K et al.
  
Since January 2020 Elsevier has created a COVID-19 resource centre with 
free information in English and Mandarin on the novel coronavirus COVID-
19. The COVID-19 resource centre is hosted on Elsevier Connect, the 
company's public news and information website. 
 
Elsevier hereby grants permission to make all its COVID-19-related 
research that is available on the COVID-19 resource centre - including this 
research content - immediately available in PubMed Central and other 
publicly funded repositories, such as the WHO COVID database with rights 
for unrestricted research re-use and analyses in any form or by any means 
with acknowledgement of the original source. These permissions are 




Clinical Guidance for the Management of Patients with Urothelial Cancers During the
COVID-19 Pandemic – Rapid Review
Karan Patel, Ananya Choudhury, Peter Hoskin, Mohini Varughese, Nicholas James,




To appear in: Clinical Oncology
Received Date: 9 April 2020
Accepted Date: 16 April 2020
Please cite this article as: Patel K, Choudhury A, Hoskin P, Varughese M, James N, Huddart R, Birtle
A, Clinical Guidance for the Management of Patients with Urothelial Cancers During the COVID-19
Pandemic – Rapid Review, Clinical Oncology, https://doi.org/10.1016/j.clon.2020.04.005.
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2020 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.
Title page  




Author names and affiliations : 
1. Karan Patel 
Afiiliation: The Rosemere Cancer Centre, Preston, Lancashire Teaching Hospitals, NHS Foundation, UK; The 
Christie NHS Foundation Trust, Manchester  
 
2. Ananya Choudhury 
Affiliaton: Division of Cancer Sciences, University of Manchester and The Christie NHS Foundation Trust, 
Manchester 
 
3. Peter Hoskin 
Affiliation: Mount Vernon Cancer Centre, Northwood, UK and Division of Cancer Sciences, University of 
Manchester 
 
4. Mohini Varughese 
Affiliation: The Beacon Centre, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, 
Taunton  
 
5. Nicholas James 
Affiliation: Institute of Cancer Research, London, UK; Royal Marsden Hospital London 
 
6. Robert Huddart 
Affiliation: Institute of Cancer Research, London, UK; Royal Marsden Hospital London 
 
7. Alison Birtle 
Affiliation: The Rosemere Cancer Centre, Preston, Lancashire Teaching Hospitals, NHS Foundation, UK & 





Present Address: The Rosemere Cancer Centre, Preston, Lancashire Teaching Hospitals, NHS Foundation, UK  




The current COVID-19 pandemic presents a substantial obstacle to cancer patient care. Data from 
China as well as risk models suppose that cancer patients, particularly those on active, 
immunosuppressive therapies are at higher risks of severe infection from the illness. In addition, 
staff illness and restructuring of services to deal with the crisis will inevitably place treatment 
capacities under significant strain. These guidelines aim to expand on those provided by NHS 
England regarding cancer care during the coronavirus pandemic by examining the known 
literature and provide guidance in managing patients with urothelial and rarer urinary tract cancers. 
In particular, they address the estimated risk and benefits of standard treatments and consider the 
alternatives in the current situation. As a result, it is recommended that this guidance will help form 
a framework for shared decision making with patients. Moreover, they do not advise a one-size-






• Severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), COVID-19 presents a significant challenge 
to cancer care 
 
• Use of cancer therapies often predicated on strong evidence base 
 
• Important to analyse risk/benefit ratio of different cancer treatments for urothelial cancer 
 
• These guidelines present framework to help decision making for urothelial cancers and other rarer urinary 
tract pathologies during COVID 19 pandemic 
 
Introduction 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly virulent, establishing the COVID-19 
pandemic within three months of the first case [1]. With the caveat of a small and heterogenous study population [2,3], 
data from China infers that patients with cancer have higher incidence and severity of the illness [4,5]. Those 
undergoing chemotherapy or surgery may have a further risk of severe events such as invasive ventilation and death 
[4]. Notably, risk models propose that most oncology patients possess an at least five percent mortality risk if infected 
with COVID-19 – equal to or greater than the benefits of many adjuvant regimens [6]. Service disruption including 
reduced access to theatres as well as high dependency care [7] is also expected to heavily impact cancer care. 
 
NHS England guidelines written in response to the extreme threat posed by COVID-19 advise the categorisation of 
cancer treatments according to the intent and risk-benefit ratio (tables 1 - 3). They also advocate considering less 
resource-intensive regimens, accounting for other patient risk factors such as age, cardiac and chest disease, offering 
treatment-breaks where appropriate, using growth factors to reduce neutropaenia and prescribing hypofractionated 
radiotherapy regimens where possible [8].  
 
The aim of this review is to place these guidelines into clinical context for patients with urothelial cancers during this 
unprecedented time. As per Gillessen and Powles, who have submitted guidance in European Urology for systemic 
treatment [9], these recommendations reflect the published literature but do not endorse a one-size-fits-all approach. 
Over the coming weeks, each department will have unique stresses and resource issues where decision-making will 
require a level of pragmatism and fluidity out with these guidelines. 
 
Management of Urothelial Cancer  
Muscle-invasive bladder cancer, T2 – T4a, is treated via radical cystectomy or radiotherapy in conjunction with 
radiosensitisation [10,11]. For locally advanced and metastatic disease, first line immunotherapy can be offered to 
those PDL-1 positive where cisplatin is unsuitable [12]. Second line options include taxane-based regimens [13] or 
atezolizumab [14]. Management of rarer urinary tract pathologies is also discussed below.  
 
T2 - T4a N0 M0 urothelial bladder cancer patients suitable for radical treatment 
Neoadjuvant chemotherapy before radical cystectomy or radical radiotherapy 
Neoadjuvant chemotherapy offers a 5% improvement in overall survival at five years [15]. Although deferral of 
patients’ definitive treatment using neoadjuvant chemotherapy may seem strategically advantageous, the potential 
period of immunosuppression is six to nine weeks depending on regimen used. Additionally, dates of radical treatment 
may be threatened because of illness from treatment. Consequently, omission of neoadjuvant chemotherapy should 
be considered - priority level 4. 
 
Radical cystectomy  
Radical cystectomy is a valid treatment option for younger fitter patients needing curative therapy - priority level 2. 
However in the present situation, the risks are substantial for older, less fit patients who often have significant co-
morbidities and a high risk of death from hospital acquired COVID-19. Acquisition of randomised, phase III data 
comparing radical cystectomy and chemo-radiotherapy has proven challenging [16]. In its absence, retrospective non-
randomised trials have shown radical radiotherapy to offer very similar cancer-specific outcomes to cystectomy 
despite older radiation techniques and minimal use of concurrent chemotherapy [17–19]. Chemo-radiotherapy has 
also demonstrated comparable outcomes [20] and even improved overall survival [21] to surgery more recently, and is 
accepted as valid alternative by the joint EAU-ESMO consensus panel [22] and NICE [10]. In the current pandemic, 
bladder preservation therapy offers a sound choice for patients. 
 
Adjuvant chemotherapy post-radical cystectomy  
NICE recommend adjuvant combination cisplatin chemotherapy after surgery for muscle-invasive or lymph-node-
positive urothelial bladder cancer where neoadjuvant chemotherapy was deemed unsuitable [10]. A meta-analysis 
observing the effect of adjuvant chemotherapy demonstrated an absolute increase in overall survival by 9% at three 
years [23]. However, patients aged 40 and over possess a greater risk of death if infected with COVID-19 than the 
benefit offered by adjuvant treatment [6]. Therefore chemotherapy post-cystectomy is not advised for most - priority 
level 4. 
 
Radical radiotherapy with Radiosensitisation 
Radiosensitisation with carbogen and nicotinamide or Mitomycin C and 5-fluorouracil (MMC-5FU) via the BCON and 
BC2001 trials has been shown to improve loco-regional recurrence-free and overall survivals [24,25]. Although 
difference in overall survival with addition of MMC-5FU to radiotherapy was non-significant (p=0.16), muscle-invasive 
recurrence essentially halved [25]. In addition, improvement in bladder cancer specific survival became significant and 
the salvage cystectomy rate reduced to 11% with longer follow-up [26]. Carbogen and nicotinamide would be ideal 
radiosensitisers at present, especially in patients with significant necrotic areas in tumour [27], because of their lack of 
immunosuppression. However, most radiotherapy departments do not have BCON up and running. Given the 
worldwide shortage of Mitomycin C, weekly gemcitabine [28] is an acceptable alternative and has been used as a 
standard option with 20 fraction radiotherapy in the RAIDER trial, a Randomised phase II trial of Adaptive Image 
guided standard or Dose Escalated tumour boost Radiotherapy in the treatment of transitional cell carcinoma of the 
bladder. Radiosensitisation cures muscle invasive bladder cancer and reduces numbers of salvage cystectomies, and 
is recommended at the highest priority - priority level 1. 
   
Radiotherapy dose and fractionation 
No statistically significant differences in locoregional disease–free survival or toxicity were seen between the 
conventionally (64 Gy in 32 fractions) and hypofractionated (55 Gy in 20 fractions) treated groups within the BC2001 
and BCON trials [24,25]. A meta-analysis by Porta et al. confirmed that hypofractionated radiotherapy was non-
inferior, and possibly superior, to conventionally fractionated radiotherapy for overall survival and late toxicity. 
Moreover, the hypofractionated population possessed better rates of invasive locoregional control [29]. Hence, 
hypofractionated radiotherapy is recommended ideally with a radiosensitiser where radical treatment is appropriate - 
priority level 1 (soft tissue image guidance (e.g. with cone beam CT) significantly improves accuracy and should be 
maintained whenever possible). 
 
Weekly radiotherapy in the form of 36Gy in six fractions or 21Gy in three fractions on alternate days has been shown 
as effective regimens in patients unsuitable for daily radical radiotherapy – albeit with limited long-term data [30,31]. 
The Hypofractionated bladder Radiotherapy with or without image guided adaptive planning (HYBRID) study reported 
over 70% of patients achieving local control at 3 months in an unfit patient group [32]. In the event of significantly 
reduced staffing and capacity, 21 Gy in three fractions or 36Gy in six fractions may be considered in patients 
unsuitable for or when daily radiotherapy is unavailable.  
 
Locally advanced or metastatic urothelial bladder cancer patients  
First line systemic treatment  
Cisplatin-containing chemotherapy, either as gemcitabine-cisplatin or methotrexate, vinblastine, adriamycin and 
cisplatin is the recognised standard in this setting [10,11]. A study comparing the two demonstrated similar response 
rates of over 50% but a better side-effect profile with gemcitabine-cisplatin [33]. Keynote-052 observed an objective 
response rate of 24% with pembrolizumab in 370 patients with metastatic bladder cancer unfit for cisplatin [34]. Given 
the change in risk/benefit of palliative chemotherapy during the COVID-19 pandemic, patients with slowly growing 
metastatic disease should be observed; with chemotherapy reserved for rapidly progressive disease, and patients 
counselled specifically for the increased risk of COVID complications leading to death. Overall, immunotherapy should 
be the primary choice in PDL1 positive disease but the possibility of severe COVID-19 infection mimicking 
immunotherapy-induced pneumonitis should be recognised. In the absence of PDL1 positivity, chemotherapy remains 
an option for symptomatic control depending on capacity levels - priority level 4. 
 
Second line systemic treatment 
Studies examining the efficacy of second line treatment are highly dependent on the characteristics of participants. 
NICE has removed approval for Pembroluzimab from 15th April 2020 but atezoluzimab remains available via the 
Cancer Drugs Fund for patients who have had platinum-containing chemotherapy. This is predicated on the IMvigor 
studies [10]. In IMvigor 211, atezolizumab exhibited more durable response but not an improved overall survival 
compared to chemotherapy [35]. Four weekly atezolizumab may be considered in view of reduced hospital visits and 
lack of immunosuppression - priority level 4.  
Overall, the risk-benefit ratio of second line single agent chemotherapy is questionable  in most cases - priority level 
6. 
 
Palliative radiotherapy for bleeding or local symptom control 
Ali et al. detailed the importance of appropriate patient selection for palliative radiotherapy for bladder cancer. Their 
study demonstrated that palliative radiotherapy including 8 Gy in a single fraction improved haematuria, dysuria and 
pain [36] - priority level 4. 
 
Upper tract urothelial cancer 
Upper tract urothelial carcinomas are rare [37] with treatment data previously lacking. The POUT trial recently 
addressed this paucity and observed a benefit of 17% on three-year disease-free survival following adjuvant 
gemcitabine-platinum for completely resected pT2–T4 pN0–N3 M0 or pTany N1–3 M0 disease [38]. Accordingly, post-
nephroureterectomy chemotherapy should be discussed with this patient cohort - priority level 3. 
 
Non-urothelial cancer of urinary tract 
The prognosis of small cell carcinoma remains poor. Previous literature has shown an important role for the use of 
neoadjuvant chemotherapy prior to surgery or radiotherapy to downstage and increase overall survival [39–41]. more 
Recent studies have not demonstrated differenced in survival rates between surgery and radiotherapy [42,43]. Thus a 
conservative approach is warranted currently - priority level 2.  
In metastatic disease, a median overall survival of 15 months was seen with both cisplatin- and carboplatin-based 
regimens [43] - priority level 4. 
 
Pure squamous cell carcinomas of the urinary tract are relatively chemo-resistant and the peri-operative systemic 
therapy is not well-established [44] - priority level 6.  
 
Data describing perioperative chemotherapy in primary bladder adenocarcinoma is scarce. Vetterlain et al. found that 
neoadjuvant chemotherapy reduced the incidence of regional or distal disease at time of surgery but had no 
statistically significant effect on overall survival [45]. A retrospective study in Korea suggested a modest benefit with 
chemotherapy in the metastatic setting [46] - priority level 6. 
 
Discussion 
The COVID-19 pandemic presents a significant challenge for cancer care and patient safety. Timely and thorough 
planning would seem paramount in order to maintain essential services and vital treatments. Examining the efficacy 
and toxicity of treatments at the earliest opportunity will allow departments to determine which therapies to prioritise, 
what services to restructure in order to help key areas and most importantly which patients will derive the most benefit 
and least harm. Fortunately, the evidence base for anti-cancer therapies is relatively robust, which facilitates decision-
making.   
 
This review highlights the literature underpinning the treatments used for urothelial cancers and provides a framework 
to aid patient discussions and treatment decisions (table 4). Overall, prioritisation of curative treatments is advised.  
Any set of recommendations cannot encapsulate all possible scenarios and liaison within and between centres is 
strongly advocated. Lastly, submission of information to local and national data sets is also encouraged in order to 
later evaluate the impact of COVID19-related treatment decisions on outcomes.
Table 1 
Table of priority groups 1- 6 for systemic anti-cancer therapy if services are disrupted during COVID-19 pandemic; 
adapted from NHS England Clinical guide for the management of non-coronavirus patients requiring acute treatment: 
Cancer 
Systemic anti-cancer treatments - Categorisation of patients  
Priority level 1  
• Curative therapy with a high (>50%) chance of success 
 
• Adjuvant (or neo) therapy which adds at least 50% chance of cure to surgery or radiotherapy alone or 
treatment given at relapse 
Priority level 2  
• Curative therapy with an intermediate (20 - 50%) chance of success 
 
• Adjuvant (or neo) therapy which adds 20 - 50% chance of cure to surgery or radiotherapy alone or treatment 
given at relapse 
Priority level 3  
• Curative therapy of a low chance (10 –20%) of success 
 
• Adjuvant (or neo) therapy which adds 10 –20% chance of cure to surgery or radiotherapy alone or treatment 
given at relapse 
 
• Non-curative therapy with a high (>50%) chance of >1 year life extension  
Priority level 4  
• Curative therapy with a very low (0-10%) chance of success 
 
• Adjuvant (or neo) therapy which adds a less than 10 chance of cure to surgery or radiotherapy alone or 
treatment given at relapse 
 
• Non-curative therapy with an intermediate (15 - 50%) chance of >1 year life extension 
Priority level 5  
• Non-curative therapy with a high (>50%) chance of palliation / temporary tumour control but <1 year  life 
extension 
Priority level 6  
• Non-curative therapy with an intermediate (15 - 50%) chance of palliation or temporary tumour control and 





Table of priority groups 1- 5 for radiotherapy if services are disrupted during COVID-19 pandemic; adapted from NHS 
England Clinical guide for the management of non-coronavirus patients requiring acute treatment: Cancer. 
 
  
Radiation therapy - Categorisation of patients  
Priority level 1  
• Patients with category 1 (rapidly proliferating) tumours currently being treated with radical 
(chemo)radiotherapy with curative intent where there is little or no scope for compensation of gaps 
 
• Patients with category 1 tumours in whom combined External Beam Radiotherapy (EBRT) and subsequent 
brachytherapy is the management plan and the EBRT is already underway 
 
• Patients with category 1 tumours who have not yet started and in whom clinical need determines that 
treatment should start in line with current cancer waiting times  
Priority level 2  
• Urgent palliative radiotherapy in patients with malignant spinal cord compression who have useful 
salvageable neurological function 
Priority level 3  
• Radical radiotherapy for Category 2 (less aggressive) tumours where radiotherapy is the first definitive 
treatment.  
 
• Post-operative radiotherapy where there is known residual disease following surgery in tumours with 
aggressive biology  
Priority level 4  
• Palliative radiotherapy where alleviation of symptoms would reduce the burden on other healthcare services, 
such as haemoptysis 
Priority level 5  
• Adjuvant radiotherapy where there has been compete resection of disease and there is a <20% risk of 
recurrence at 10 years, for example most ER positive breast cancer in patients receiving endocrine therapy 
 
• Radical radiotherapy for prostate cancer in patients receiving neo-adjuvant hormone therapy 
Table 3 
Table of priority groups 1- 3 for radiotherapy if services are disrupted during COVID-19 pandemic; adapted from NHS 
England Clinical guide for the management of non-coronavirus patients requiring acute treatment: Cancer. 
  
Surgical patients - Categorisation of patients  
Priority level 1a 
• Emergency: operation needed within 24 hours to save life  
 
Priority level 1b 
• Urgent: operation needed within 72 hours 
 
Examples 
Urgent/emergency surgery for life threatening conditions such as obstruction, bleeding and regional and/or 
localised infection/ permanent injury/clinical harm from progression of conditions such as spinal cord 
compression 
Priority level 2  
• Elective surgery with the expectation of cure, prioritised according to: 
o Surgery within 4 weeks to save life or before progression of disease beyond operability depending 
on: 
 urgency of symptoms 
 complications such as local compressive symptoms 
 biological priority (expected growth rate) of individual cancers 
 
Local complications may be temporarily controlled, for example with stents if surgery is deferred and/or 
interventional radiology 
Priority level 3  
• Elective surgery can be delayed for 10-12 weeks with no predicted negative outcome 
 
Table 4 
Table summarising priority level recommendations for management of urothelial cancers during COVID-19 pandemic. 
 Surgery  Radiation therapy 
 
Systemic treatment 
Priority level 1 
 • Radical radiotherapy with 
Radiosensitisation 
 
Priority level 2 • Radical 
Cystectomy 
 • Neoadjuvant chemotherapy for small 
cell cancer of bladder 
Priority level 3 
  
 
• Adjuvant chemotherapy post-nephro-
ureterectomy (pT2–T4 pN0–N3 
M0/pTany N1–3 M0) 
Priority level 4 
 • Palliative radiotherapy for 
bleeding or local control 
 
• Neoadjuvant chemotherapy for 
urothelial MIBC 
 
• Adjuvant chemotherapy post-radical 
cystectomy for urothelial MIBC 
 
• First line systemic treatment for 
metastatic urothelial cancer of 
bladder 
 
• First line systemic treatment for 
metastatic small cell cancer of 
bladder 
 
• Adjuvant chemotherapy post-radical 
cystectomy  
 
• Neoadjuvant chemotherapy for 
adenocarcinoma cancer of bladder 
 
• Second line immune therapy 
treatment for metastatic urothelial 
cancer of bladder 
Priority level 5 
  
 
Priority level 6 
  • Neoadjuvant/adjuvant chemotherapy 
for squamous cell cancer of bladder 
 
• First line systemic treatment for 
metastatic adenocarcinoma cancer of 
bladder 
• Second/third line chemotherapy 
treatment for metastatic urothelial 
cancer of bladder 
 
Abbreviation: MIBC – muscle invasive bladder cancer 
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• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19 presents a significant challenge 
to cancer care 
 
• Use of cancer therapies often predicated on strong evidence base 
 
• Important to analyse risk/benefit ratio of different cancer treatments for urothelial cancer 
 
• These guidelines present framework to help decision making for urothelial cancers and other rarer urinary 
tract pathologies during COVID 19 pandemic 
 
